The Immune Landscape of Cancer
- V. Thorsson, David L. Gibbs, V. Jakrot
- BiologyImmunity
- 1 April 2018
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
In patients with advanced melanoma, including those who had had disease progression while they had been receiving ipilimumab, treatment with lambrolizumab resulted in a high rate of sustained tumor regression, with mainly grade 1 or 2 toxic effects.
Comprehensive Characterization of Cancer Driver Genes and Mutations
- Matthew H. Bailey, C. Tokheim, A. Mariamidze
- BiologyCell
- 5 April 2018
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.
- J. Sosman, Kevin B. Kim, A. Ribas
- MedicineNew England Journal of Medicine
- 23 February 2012
Vemurafenib induces clinical responses in more than half of patients with previously treated BRAF V600-mutant metastatic melanoma, and the median overall survival in this study with a long follow-up was approximately 16 months.
Genomic Classification of Cutaneous Melanoma
- R. Akbani, K. Akdemir, L. Zou
- BiologyCell
- 18 June 2015
Improved survival with MEK inhibition in BRAF-mutated melanoma.
- K. Flaherty, C. Robert, D. Schadendorf
- Medicine, BiologyNew England Journal of Medicine
- 11 July 2012
Tametinib, as compared with chemotherapy, improved rates of progression-free and overall survival among patients who had metastatic melanoma with a BRAF V600E or V600K mutation.
Oncogenic Signaling Pathways in The Cancer Genome Atlas
- F. Sánchez-Vega, Marco Mina, A. Mariamidze
- BiologyCell
- 5 April 2018
Whole-genome landscapes of major melanoma subtypes
- N. Hayward, J. Wilmott, G. Mann
- BiologyNature
- 3 May 2017
Analysis of whole-genome sequences from cutaneous, acral and mucosal subtypes of melanoma reveals diverse carcinogenic processes across its subtypes, some unrelated to sun exposure, and extends potential involvement of the non-coding genome in its pathogenesis.
Completion Dissection or Observation for Sentinel‐Node Metastasis in Melanoma
- M. Faries, J. Thompson, R. Elashoff
- MedicineNew England Journal of Medicine
- 8 June 2017
Immediate completion lymph‐node dissection increased the rate of regional disease control and provided prognostic information but did not increase melanoma‐specific survival among patients with melanoma and sentinel‐node metastases.
Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
- J. Wilmott, G. Long, R. Scolyer
- Medicine, BiologyClinical Cancer Research
- 12 December 2011
The increase in tumor-infiltrating lymphocytes induced by treatment with BRAf inhibitors provides strong support for conducting trials that combine BRAF inhibitors with immunotherapy in the hope of prolonging clinical responses.
...
...